首页> 外文期刊>国际肝胆胰疾病杂志(英文版) >Effect of Sirpα1 on the expression of nuclear factor-kappa B in hepatocellular carcinoma
【24h】

Effect of Sirpα1 on the expression of nuclear factor-kappa B in hepatocellular carcinoma

机译:Sirpα1对肝细胞癌中核因子-κB表达的影响

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: Signal regulatory protein alpha1 (Sirpα1) is a member of Sirps families containing four immunoreceptor tyrosine-based inhibitory motifs (ITIMs) domains in the cytoplasm of and an activated substrate of receptor tyrosine kinase (RTK), that negatively regulates the RTK-dependent cell proliferating signal transduction pathway. Previously we found that Sirpα1 was closely associated with the occurrence and development of hepatocellular carcinoma (HCC) as well as liver regeneration. Since it is unclear about the regulatory mechanisms, we established the cell line transfected Sirpα1 gene and preliminarily clariifed the mechanisms by which Sirpα1 negatively regulates the carcinogenesis and development of HCC. METHODS: Liver cancer Sk-Hep1 cell was respectively transfected with plasmids of pLXSN, pLXSN-Sirpα1 and pLXSN-Sirpα1Δ4Y2, screened with the drug of G418 (1200μg/ml), and various transfected Sk-Hep1 cell lines were obtained. The protein expressions of P65, P50, IκBα, cyclin D1 and Fas in various Sk-Hep1 cell lines were determined by Western blotting, and P65 and P50 were localized by the immunolfuorescence technique. RESULTS: Sirpα1 could signiifcantly upregulate the protein expression of IκBα (vs. other cell lines, P<0.05) in the Sk-Hep1 cell, and downregulate the protein expressions of P65, P50 and cyclin D1 (vs. other cell lines, P<0.05) in the Sk-Hep1 cell. P65 protein expression was mainly localized in the cytoplasm in the pLXSN Sk-Hep1 cell, and in the nucleus of the Sk-Hep1 cell with mutant Sirpα1Δ4Y2, but in nucleus of the Sk-Hep1 cell with wild Sirpα1. P50 protein expression was localized in the cytoplasm and nucleus of the pLXSN Sk-Hep1 cell, but in the nucleus of the Sk-Hep1 cell with wild Sirpα1 and mutant Sirpα1Δ4Y2 plasmid. CONCLUSIONS: Sirpα1 might negatively regulate and control the abnormal proliferation of liver cancer cells by inlfuencing the protein content and localization of nuclear factor-kappa B, then inlfuence the expression of cyclins such as cyclin D1 in the signal transduction pathway. It may be one of the important mechanisms by which Sirpα1 negatively regulates the carcinogenesis and development of HCC.
机译:背景:信号调节蛋白α1(Sirpα1)是Sirps家族的成员,在其细胞质中具有四个基于免疫酪氨酸的抑制性基序(ITIMs)结构域,并激活了受体酪氨酸激酶(RTK)的底物,从而对RTK依赖性产生负调节作用细胞增殖信号转导途径。先前我们发现Sirpα1与肝细胞癌(HCC)的发生和发展以及肝再生密切相关。由于尚不清楚其调控机制,我们建立了转染Sirpα1基因的细胞系,并初步阐明了Sirpα1负调控HCC癌变和发展的机制。 方法:分别用pLXSN,pLXSN-Sirpα1和pLXSN-Sirpα1Δ4Y2质粒转染肝癌Sk-Hep1细胞,用G418(1200μg/ ml)药物筛选,获得各种转染的Sk-Hep1细胞株。通过Western blotting检测各种Sk-Hep1细胞株中P65,P50,IκBα,细胞周期蛋白D1和Fas蛋白的表达,并通过免疫荧光技术定位P65和P50的表达。 结果:Sirpα1可以显着上调Sk-Hep1细胞中IκBα的蛋白表达(相对于其他细胞系,P <0.05),而下调P65,P50和cyclin D1的蛋白表达(相对于其他细胞系)。 ,P <0.05)在Sk-Hep1细胞中。 P65蛋白的表达主要位于pLXSN Sk-Hep1细胞的细胞质中,以及具有突变Sirpα1Δ4Y2的Sk-Hep1细胞核中,而位于野生Sirpα1的Sk-Hep1细胞核中。 P50蛋白表达位于pLXSN Sk-Hep1细胞的细胞质和细胞核中,但位于具有野生Sirpα1和突变Sirpα1Δ4Y2质粒的Sk-Hep1细胞的细胞核中。 结论:Sirpα1可能通过影响蛋白质含量和核因子κB的定位,从而负调控肝癌细胞的异常增殖,进而影响细胞周期蛋白如cyclin D1的表达。这可能是Sirpα1负调控肝癌发生发展的重要机制之一。

著录项

  • 来源
    《国际肝胆胰疾病杂志(英文版)》 |2007年第003期|276-283|共8页
  • 作者单位

    Department of Hepatobiliary and Pancreatic Surgery, Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing 100020, China Qin JM;

    and Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China Wan XW, Zeng JZ and Wu MC;

    Department of Hepatobiliary and Pancreatic Surgery, Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing 100020, China Qin JM;

    and Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China Wan XW, Zeng JZ and Wu MC;

    Department of Hepatobiliary and Pancreatic Surgery, Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing 100020, China Qin JM;

    and Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China Wan XW, Zeng JZ and Wu MC;

    Department of Hepatobiliary and Pancreatic Surgery, Beijing Chaoyang Hospital, Capital University of Medical Sciences, Beijing 100020, China Qin JM;

    and Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai 200438, China Wan XW, Zeng JZ and Wu MC;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

  • 入库时间 2022-08-19 03:39:24
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号